HC Wainwright & Co. maintains Elicio Therapeutics at Buy, lowers price target to $21 from $23
HC Wainwright & Co. maintained its Buy rating for Elicio Therapeutics but lowered its price target to $21 from $23, an 8.7% decrease. The new target implies a 1176.6% upside from the Nov 9 close of $1.65.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short‑term selling pressure but also highlights a substantial upside if the company meets expectations.
Market read
Analyst price‑target reduction is a modest catalyst for a micro‑cap biotech, offering limited but actionable insight for short‑term traders.
What to watch
Potential upcoming clinical data or partnership announcements could offset the price‑target cut.
Background
Elicio Therapeutics is a micro‑cap biotech whose valuation is highly sensitive to analyst opinions and trial outcomes.
Market effects
May weigh on other small‑cap biotech stocks as analysts tighten targets.
Limited to U.S. biotech sector.
Low
Counterpoint
The large upside implied by the current price could attract contrarian buyers despite the downgrade.
Key entities
- analystHC Wainwright & Co.
Equity research firm that issued the price‑target change.
- companyElicio Therapeutics
Biotech firm subject of the analyst downgrade.